Disitamab vedotin combinations for HER2-positive breast cancer that spread to the brain
Tests disitamab vedotin combinations in HER2-positive breast cancer reaching the brain.
Key facts
- Who runs it
- Xi'an International Medical Center Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis
- Status
- Not yet recruiting
- People taking part
- 20 people, planned
- Started
- Sept 2023
- Expected to end
- Apr 2027
- Type of study
- Interventional
- Treatments tested
- Disitamab Vedotin plus pyrotinib or naratinib
- Record updated
- 29 August 2023
Who can take part
The trial is looking for women with HER2-positive breast cancer that has spread to the brain. They will get Disitamab Vedotin plus pyrotinib or neratinib.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Metastatic breast cancer with brain metastases seen on MRI or enhanced CT, with at least one measurable brain lesion (RECIST 1.1). Cohort A: newly found brain metastases. Cohort B: brain metastases that grew after whole-brain radiotherapy or stereotactic radiosurgery. Daily activity score (ECOG) 0 to 2. Expected survival of at least 3 months.
- Earlier treatment
- People cannot join if they had an anti-HER2 ADC drug before, or had pyrotinib and neratinib one after the other. No chemotherapy, major surgery or targeted therapy within 2 weeks, no hormone (endocrine) therapy within 1 week, and no nitrosoureas or mitomycin within 6 weeks before joining.
- Biomarker or test result
- HER2-positive: immunohistochemistry staining of 3+, or positive by FISH test, in the primary or metastatic tumour.
- Main reasons for not taking part
- Widespread spread to the brain lining (leptomeningeal) and poor response to steroid treatment
- Fluid build-up in the chest or belly that cannot be controlled
- Another cancer within the past 5 years, with some exceptions
- Heart attack in the past 6 months, uncontrolled heart failure or severe uncontrolled heart rhythm problems
- Pregnant or breastfeeding, or allergy to the trial drugs
Show the full registry criteria (25)Hide the full registry criteria
Who can take part
- Patients who can voluntarily sign an informed consent form
- Females aged ≥18 years old when signing the informed consent form
- ECOG PS physical status score of 0 to 2 points
- Histologically confirmed HER2-positive metastatic breast cancer patients; Note: HER2 positivity refers to at least one occurrence of tumor cell immunohistochemical staining intensity of 3+ or confirmed as positive by fluorescence in situ hybridization [FISH] in the pathological testing/re-review of the primary or metastatic lesions conducted by the participating center's pathology department
- Brain metastases confirmed by MRI/enhanced CT, with at least one measurable lesion in the brain based on RECIST 1.1 criteria
- Expected survival period ≥3 months
- Patient types: Cohort A - newly diagnosed brain metastases patients; Cohort B - patients with progression after whole-brain radiotherapy or stereotactic radiosurgery
- Left ventricular ejection fraction (LVEF) ≥50%
- QT interval corrected by Fridericia formula (QTcF) of 12-lead electrocardiogram: <450ms for males, <470ms for females
- The following conditions should be met in the blood routine examination:① Absolute neutrophil count (ANC) ≥1.5×10\^9/L, ② Platelet count ≥100×10\^9/L, ③ Hemoglobin ≥90g/L, ④ White blood cell count ≥3.0×10\^9/L
- Liver function meets the following conditions: ① Serum total bilirubin ≤1.5×upper limit of normal (ULN), or ≤3×ULN if there are liver metastases, ② Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤3×ULN, or ≤5×ULN if there are liver metastases
- Renal function meets the following conditions: Serum creatinine ≤1.5×ULN or creatinine clearance ≥50mL/min (calculated according to the Cockroft-Gault formula)
- Female patients who meet the following conditions can participate in this study: ① Infertility; ② Capable of fertility, with a negative blood pregnancy test result within 7 days before the first administration of the investigational drug, not breastfeeding, and adopting effective contraceptive measures during the screening period, throughout the study, and within 6 months after the last administration of the study drug
Who cannot take part
- Patients who have received treatment with anti-HER2 ADC drugs
- Patients who have received sequential treatment with pyrotinib and neratinib
- Patients with extensive leptomeningeal metastases and poor response to steroid dehydration therapy for brain metastases
- Patients who have received chemotherapy, major surgery, or molecular targeted therapy within 2 weeks prior to enrollment; patients who have received endocrine therapy within 1 week prior to enrollment; patients who have received nitrosoureas or mitomycin chemotherapy within 6 weeks prior to enrollment
- Concurrent use of any other anticancer treatment
- History of or current concurrent malignancies within the past 5 years, excluding cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder carcinoma [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading the lamina propria)]
- Underwent major surgery (including thoracotomy biopsy), experienced significant trauma (such as fractures), had unhealed wounds or fractures at the time of screening, or anticipated the need for major surgery during the study treatment period, within the 4 weeks prior to randomization
- Known history of hypersensitivity reactions to any investigational drugs
- Known allergy to the drugs and excipients involved in this trial
- History of myocardial infarction within the past 6 months; history of New York Heart Association (NYHA) class ≥II congestive heart failure that is not controlled by medication, severe arrhythmias that cannot be controlled (excluding atrial fibrillation and paroxysmal supraventricular tachycardia); known decrease in LVEF to below 50% during or after previous treatment with trastuzumab
- Presence of third space fluid accumulation (such as significant pleural effusion or ascites) that cannot be controlled by drainage or other methods
- Subjects deemed unsuitable for participation by other investigators
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Sex
- Breast cancer
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Basis: Brain metastasis is very common in breast cancer, and HER2 positivity is a risk factor for high incidence of brain metastasis, with approximately 50% of HER2+ MBC cases experiencing brain metastasis. The reason for this is that as the efficacy of HER2-targeted therapy improves, the survival of these patients significantly extends, leading to an increase in the occurrence rate of brain metastasis events in the late stage of MBC. In the systemic treatment of HER2+ breast cancer brain metastasis, various HER2-targeted drugs have been explored, but none have achieved satisfactory therapeutic effects. Therefore, it is imperative to explore new treatment options. ADC drugs have shown some efficacy in brain metastasis patients, and as a domestically developed ADC drug, trastuzumab vedotin has demonstrated good anti-tumor effects. The treatment model combining trastuzumab vedotin with small molecule TKIs has been rarely reported, so we are attempting to use the treatment model of trastuzumab vedotin combined with pyrotinib or neratinib to explore its efficacy and safety in patients with HER2-positive brain metastasis.
Read full original descriptionShow less
Method: The plan is to recruit HER2-positive breast cancer patients with brain metastasis and use the treatment of trastuzumab vedotin combined with pyrotinib or neratinib (specific treatment drugs to be selected during the study).
Procedure: All subjects will undergo screening, treatment, and follow-up periods, strictly adhering to relevant GCP regulations during the treatment process.
Expectations: Through this study, preliminary efficacy and safety data of trastuzumab vedotin combined with pyrotinib or neratinib treatment will be provided for patients with HER2+ brain metastatic BC.
The group in the trial
- Label 1Treatment being tested
tale Disitamab Vedotin with pyrotinib or neratinib
Treatment: Disitamab Vedotin plus pyrotinib or naratinib
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis
- Plain-language title
- Disitamab vedotin combinations for HER2-positive breast cancer that spread to the brainGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06015113, who can take part
- Record updated
- 29 August 2023